Table 1. Clinical characteristics and laboratory data at baseline and after LAGB intervention in MHO and IRO subjects.
| Variables | MHO Baseline | MHO 6-months follow-up | § P | IRO Baseline | IRO 6-months follow-up | § P |
| Male/Female | 8/40 | --- | 40/119 | --- | ||
| Age (years) | 38±10 | --- | 40±10 | --- | ||
| Body weight (kg) | 108±16 | 92±14 | <0.0001 | 118±20** | 102±17*** | <0.0001 |
| BMI (kg/m2) | 41.1±5.5 | 35.0±5.3 | <0.0001 | 44.0±6.4** | 38.2±5.6** | <0.0001 |
| Waist circumference (cm) | 115±12 | 100±10 | <0.0001 | 123±13** | 109±12*** | <0.0001 |
| Fasting Glucose (mgl/dl) | 93±12 | 88±12 | 0.009 | 102±14*** | 95±12** | <0.0001 |
| 2 h glucose (mgl/dl) | 105±20 | 101±30 | 0.32 | 130±39*** | 118±37** | 0.001 |
| Fasting Insulin (µU/ml) | 11±3 | 8±3 | 0.001 | 20±12*** | 12±6*** | <0.0001 |
| 2-h insulin (µU/ml) | 27±17 | 31±23 | 0.32 | 78±57*** | 57±46*** | <0.0001 |
| Total cholesterol (mg/dl) | 202±41 | 203±45 | 0.88 | 203±38 | 202±35 | 0.59 |
| HDL (mg/dl) | 48±12 | 52±12 | 0.02 | 49±12 | 51±13 | 0.002 |
| Triglycerides (mg/dl) | 119±53 | 100±46 | <0.0001 | 140±69 | 115±49 | <0.0001 |
| ALT (UI/l) | 28±14 | 22±14 | 0.009 | 36±25* | 24±14 | <0.0001 |
| AST (UI/l) | 22±7 | 19±7 | 0.005 | 26±15 | 19±8 | <0.0001 |
| ISI | 108±31 | 141±51 | 0.02 | 47±18*** | 84±46*** | <0.0001 |
| Stumvoll first-phase index | 1140±332 | 1142±395 | 0.96 | 1740±845*** | 1412±684* | <0.0001 |
| Disposition index | 121708±40793 | 153107±60566 | 0.01 | 73870±30773*** | 105675±54677** | <0.0001 |
Data are means ± SD. Triglycerides, ALT, AST, fasting, and 2-h insulin were log transformed for statistical analysis, but values in the table represent a back transformation to the original scale. Categorical variables were compared by χ2 test. §P values for differences between baseline and follow-up variables tested by paired t-test. *P values for differences of continuous variables between the two groups using unpaired Student's t.
*P <0.01 vs. MHO,
**P <0.001 vs. MHO;
***P <0.0001 vs. MHO.